7月28日，康诺亚-B盘中下跌5.59%，报77.7港元，成交额4.76亿港元。
消息面上，公司当日公告其与阿斯利康合作开发的靶向CLDN18.2抗体偶联药物CMG901全球III期临床试验CLARITY-Gastric01取得积极顶线结果。试验显示，CMG901在二线及后线CLDN18.2阳性晚期胃癌患者中，较研究者选择的治疗方案实现了具有统计学显著性的总生存期改善，安全特征与既往研究一致，未发现新安全信号。公司预计该药峰值年销售额达30亿至50亿美元。尽管临床数据积极，股价呈现典型的利好兑现回落走势，市场或已提前定价该预期。此前公司已收到吉利德收购Ouro Medicines带来的2.57亿美元首付款，基本面持续改善。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.